These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 29787390)

  • 1. Genitourinary Syndrome of Menopause.
    Shifren JL
    Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of the genitourinary syndrome of menopause.
    Palacios S; Mejía A; Neyro JL
    Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on management of genitourinary syndrome of menopause: A practical guide.
    Palacios S; Castelo-Branco C; Currie H; Mijatovic V; Nappi RE; Simon J; Rees M
    Maturitas; 2015 Nov; 82(3):308-13. PubMed ID: 26261035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.
    Danan ER; Sowerby C; Ullman KE; Ensrud K; Forte ML; Zerzan N; Anthony M; Kalinowski C; Abdi HI; Friedman JK; Landsteiner A; Greer N; Nardos R; Fok C; Dahm P; Butler M; Wilt TJ; Diem S
    Ann Intern Med; 2024 Oct; 177(10):1400-1414. PubMed ID: 39250810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G; Graham S; Koltun WD; Kingsberg SA
    J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMS - Consensus statement.
    Pitkin J;
    Post Reprod Health; 2018 Sep; 24(3):133-138. PubMed ID: 30244644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia.
    Wallace SL; St Martin B; Lee K; Sokol ER
    Am J Obstet Gynecol; 2020 Dec; 223(6):890.e1-890.e12. PubMed ID: 32562659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
    Tan O; Bradshaw K; Carr BR
    Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV; Kagan R
    Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
    Reid RL; Black D; Derzko C; Portman D
    J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current aspects of the treatment of urogenital atrophy (based on the consensus of britain society of menopause)].
    Balan VE; Tikhomirova EV; Tsarkova AV; Gadgieva ZK
    Urologiia; 2019 Dec; (5):150-154. PubMed ID: 31808652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of dyspareunia secondary to vulvovaginal atrophy.
    Fantasia HC
    Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
    Portman DJ; Gass ML;
    J Sex Med; 2014 Dec; 11(12):2865-72. PubMed ID: 25155380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
    Portman DJ; Gass ML;
    Maturitas; 2014 Nov; 79(3):349-54. PubMed ID: 25179577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
    The NAMS 2020 GSM Position Statement Editorial Panel
    Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
    Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
    Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.